Monte Rosa Therapeutics (GLUE) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Monte Rosa Therapeutics (GLUE) has outperformed MeiraGTx (MGTX) over the past year, gaining 33.9% versus a gain of 27.1%. Over five years, MGTX leads with a -26.5% price change compared with -51.3% for GLUE. MeiraGTx is the larger company by market cap ($1.01 billion vs $880.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLUE | MGTX |
|---|---|---|
| Share price | $10.32 | $10.50 |
| Market cap | $880.43M | $1.01B |
| 1-day change | +1.47% | -2.96% |
| YTD return | -34.18% | +32.08% |
| 1-year return | +33.85% | +27.12% |
| 5-year return | -51.32% | -26.47% |
| P/E ratio (TTM) | — | 12.07 |
| EPS (TTM) | $-1.75 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.77 | $15.35 |
| 52-week low | $8.53 | $6.62 |
| Distance from 52-week high | -59.95% | -31.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +171.32% | +164.29% |
| Average volume | 1.33M | 792.38K |
| Shares outstanding | 85.31M | 96.04M |
| Employees | 173 | 393 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 173 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
GLUE vs MGTX FAQ
Which is bigger, Monte Rosa Therapeutics or MeiraGTx?
MeiraGTx (MGTX) is larger, with a market capitalization of $1.01B compared with $880.43M for Monte Rosa Therapeutics (GLUE).
Which stock has performed better over the past year, GLUE or MGTX?
GLUE returned +33.85% over the past 12 months, compared with +27.12% for MGTX (price return, excluding dividends). Past performance does not predict future results.
Are Monte Rosa Therapeutics and MeiraGTx in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.